Piper Sandler & Co’s Keros Therapeutics KROS Stock Holding History

Piper Sandler & Co’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,000	Closed	-$77K	–	26
2020 Q3	$77K	Buy	+2,000	New	+$79.3K	0.06%	21

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Piper Sandler & Co's KROS Position: Q4 2020 in Review

Piper Sandler & Co sold out of Keros Therapeutics (KROS) in Q4 2020, closing a stake of 2,000 shares — an estimated $77K sold.

Piper Sandler & Co first reported a position in KROS in Q3 2020 and held it in 1 quarter. The position peaked at $77K in Q3 2020. 81 funds tracked by Wall St. Rank hold KROS as of Q4 2020.

Piper Sandler & Co reported no remaining Keros Therapeutics position as of Q4 2020 after selling out during the quarter.
Piper Sandler & Co sold 2,000 Keros Therapeutics shares in Q4 2020, an estimated $77K.
Piper Sandler & Co first reported a position in Keros Therapeutics in Q3 2020 and held it in 1 quarter.
Piper Sandler & Co's Keros Therapeutics position peaked at $77K in Q3 2020.
81 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2020.

Based on Piper Sandler & Co's 13F filing for Q4 2020, filed 11 Feb 2021.